A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006)
Latest Information Update: 18 Jun 2024
At a glance
- Drugs Rilparencel (Primary)
- Indications Renal failure
- Focus Registrational; Therapeutic Use
- Acronyms proact 1; REACT; REGEN-006
- Sponsors ProKidney
- 17 Jun 2024 According to Prokidney media release, company announced the closing of $140 Million public offering of class A ordinary shares and concurrent registered direct offering to develop rilparencel for patients with advanced chronic kidney disease
- 17 Jun 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 10 Jun 2024 Planned number of patients changed from 600 to 685.